PubMed:23953270 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23953270","sourcedb":"PubMed","sourceid":"23953270","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23953270","text":"Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).\nUNLABELLED: This randomised 12-month open study analysed the effectiveness of quetiapine XR (400-800 mg) versus risperidone (2-6 mg) on subjective well-being in schizophrenia (NCT00600756). Primary objective was to demonstrate non-inferiority of quetiapine XR to risperidone in 6-month responder rate using the Subjective Well-Being under Neuroleptics scale (SWN-K) (per-protocol at Month 6 [PP 6] population). Non-inferiority was defined as the lower limit of the 95% confidence interval (CI) greater than -9.7% for the adjusted difference between quetiapine XR and risperidone. Secondary objectives included non-inferiority of quetiapine XR versus risperidone (lower limit of 95% CI greater than -7.5 points) for SWN-K change from baseline to Month 12 (PP 12). 798 patients were randomised (quetiapine XR, n=395; risperidone, n=403); at Month 12, 212 (54%) and 227 (56%) patients, respectively, completed the study. At Month 6, SWN-K responder rate in the PP 6 population was 65% (136/210) with quetiapine XR and 68% (158/232) with risperidone (adjusted treatment difference: -5.7%; 95% CI: -15.1, 3.7); thus, non-inferiority could not be established. SWN-K change from baseline to Month 12 was 23.2 points for quetiapine XR and 21.1 points for the risperidone group; treatment difference was 2.1 (95% CI: -0.8; 5.0); non-inferiority was established (PP 12).\nCONCLUSION: SWN-K response at 6 months was comparable between the two antipsychotics. However, with a lower than expected responder rate and a lower than expected number of evaluable patients in the PP 6 population, non-inferiority was not demonstrated. A secondary objective (SWN-K total score) established non-inferiority of quetiapine XR to risperidone at Month 12.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_23953270_4_0","span":{"begin":627,"end":646},"obj":"expanded"},{"id":"SS2_23953270_4_0","span":{"begin":648,"end":650},"obj":"abbr"}],"relations":[{"id":"AE1_23953270_4_0","pred":"abbreviatedTo","subj":"SS1_23953270_4_0","obj":"SS2_23953270_4_0"}],"attributes":[{"subj":"SS1_23953270_4_0","pred":"source","obj":"Allie"},{"subj":"SS2_23953270_4_0","pred":"source","obj":"Allie"}]},{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":319,"end":332},"obj":"HP_0100753"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"}]},{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":236,"end":249},"obj":"CI"},{"id":"T2","span":{"begin":116,"end":129},"obj":"CI"},{"id":"T3","span":{"begin":404,"end":417},"obj":"CI"},{"id":"T4","span":{"begin":707,"end":720},"obj":"CI"},{"id":"T5","span":{"begin":787,"end":800},"obj":"CI"},{"id":"T6","span":{"begin":951,"end":964},"obj":"CI"},{"id":"T7","span":{"begin":1155,"end":1168},"obj":"CI"},{"id":"T8","span":{"begin":1371,"end":1384},"obj":"CI"},{"id":"T9","span":{"begin":1846,"end":1859},"obj":"CI"},{"id":"T10","span":{"begin":270,"end":281},"obj":"CI"},{"id":"T11","span":{"begin":135,"end":146},"obj":"CI"},{"id":"T12","span":{"begin":421,"end":432},"obj":"CI"},{"id":"T13","span":{"begin":725,"end":736},"obj":"CI"},{"id":"T14","span":{"begin":808,"end":819},"obj":"CI"},{"id":"T15","span":{"begin":973,"end":984},"obj":"CI"},{"id":"T16","span":{"begin":1192,"end":1203},"obj":"CI"},{"id":"T17","span":{"begin":1409,"end":1420},"obj":"CI"},{"id":"T18","span":{"begin":1863,"end":1874},"obj":"CI"},{"id":"T19","span":{"begin":25,"end":38},"obj":"DP"},{"id":"T20","span":{"begin":319,"end":332},"obj":"DP"}],"attributes":[{"subj":"T1","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T2","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T3","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T4","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T5","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T6","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T7","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T8","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T9","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T10","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T11","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T12","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T13","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T14","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T15","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T16","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T17","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T18","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T19","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T20","pred":"source","obj":"Zierdiyeerkenaili_800_3"}]},{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":25,"end":38},"obj":"DP"},{"id":"T10","span":{"begin":725,"end":736},"obj":"CI"},{"id":"T11","span":{"begin":787,"end":800},"obj":"CI"},{"id":"T12","span":{"begin":808,"end":819},"obj":"CI"},{"id":"T13","span":{"begin":1155,"end":1168},"obj":"CI"},{"id":"T14","span":{"begin":1192,"end":1203},"obj":"CI"},{"id":"T15","span":{"begin":1371,"end":1384},"obj":"CI"},{"id":"T16","span":{"begin":1409,"end":1420},"obj":"CI"},{"id":"T17","span":{"begin":1846,"end":1859},"obj":"CI"},{"id":"T18","span":{"begin":1863,"end":1874},"obj":"CI"},{"id":"T19","span":{"begin":319,"end":332},"obj":"DP"},{"id":"T2","span":{"begin":116,"end":129},"obj":"CI"},{"id":"T20","span":{"begin":236,"end":249},"obj":"CI"},{"id":"T21","span":{"begin":951,"end":964},"obj":"CI"},{"id":"T22","span":{"begin":270,"end":281},"obj":"CI"},{"id":"T23","span":{"begin":973,"end":984},"obj":"CI"},{"id":"T3","span":{"begin":135,"end":146},"obj":"CI"},{"id":"T7","span":{"begin":404,"end":417},"obj":"CI"},{"id":"T8","span":{"begin":421,"end":432},"obj":"CI"},{"id":"T9","span":{"begin":707,"end":720},"obj":"CI"}],"attributes":[{"subj":"T1","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T10","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T11","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T12","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T13","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T14","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T15","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T16","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T17","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T18","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T19","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T2","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T20","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T21","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T22","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T23","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T3","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T7","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T8","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T9","pred":"source","obj":"yaoziqian_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#ec93c8","default":true},{"id":"PubmedHPO","color":"#93e2ec"},{"id":"Zierdiyeerkenaili_800_3","color":"#ecdc93"},{"id":"yaoziqian_800_3","color":"#c293ec"}]}]}}